Storage and handling
Other information avoid storing product in direct sunlight protect from excessive moisture
Other information avoid storing product in direct sunlight protect from excessive moisture
Active ingredients Purpose
Camphor 1.2%...........................................Topical analgesic
Menthol 5.7%.............................................Topical analgesic
Methyl Salicylate 6.3%.................................Topical analgesic
Uses
For temporary relief of minor aches and pains of muscles and joints associated with:
Warnings
For external use only
Allergy alert: If prone to allergic reaction from aspirin or salicylates, consult a doctor before use.
Do not use
When using this product
Stop use and ask a doctor if:
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children.
If swallowed, get medical help or contact a Poision Control Center right away.
Directions
Adults and children 12 years of age and over:
Children under 12 years of age: consult with a doctor
Other information
Inactive ingredients
butylated hydroxytoluene, glyceryl rosinate, natural rubber, polybutene, polyisobutylene, precipitated calcium carbonate, quinton, sorbitan
stearate, tocopherol acetate, YS resin, zinc oxide
DISTRIBUTED BY:
UNITED EXCHAGE CORP.
17211 VALLY VIEW AVE.
CERRITOS, CA 90703
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 65923-155-02 | 2022-04-06 | C162847 | 48780-1 | d6a99b39-33cc-a426-e053-dadaa90af4c2 | fc23a69c-d311-4e96-9cf4-a8591a1fac3a |
| 65923-155-02 | 2022-01-28 | C162847 | 48780-1 | d6a99b39-33cc-a426-e053-dadaa90af4c2 | fc23a69c-d311-4e96-9cf4-a8591a1fac3a |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CAMPHOR (NATURAL) | ACTIVE INGREDIENT | N20HL7Q941 | 3 | |
| MENTHOL | ACTIVE INGREDIENT | L7T10EIP3A | 3 | |
| METHYL SALICYLATE | ACTIVE INGREDIENT | LAV5U5022Y | 3 | |
| CAMPHOR (NATURAL) | ACTIVE MOIETY | N20HL7Q941 | 3 | |
| MENTHOL | ACTIVE MOIETY | L7T10EIP3A | 3 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 3 | |
| CALCIUM CARBONATE | INACTIVE INGREDIENT | H0G9379FGK | 3 | |
| GLYCERYL ABIETATE | INACTIVE INGREDIENT | 2F22LY70Q1 | 3 | |
| ISOPROPYL MYRISTATE | INACTIVE INGREDIENT | 0RE8K4LNJS | 3 | |
| NATURAL LATEX RUBBER | INACTIVE INGREDIENT | 2LQ0UUW8IN | 3 | |
| POLYBUTENE (1400 MW) | INACTIVE INGREDIENT | 1NA5AO9GH7 | 3 | |
| PROPYLENE CARBONATE | INACTIVE INGREDIENT | 8D08K3S51E | 3 | |
| SODIUM STEARATE | INACTIVE INGREDIENT | QU7E2XA9TG | 3 | |
| ZINC OXIDE | INACTIVE INGREDIENT | SOI2LOH54Z | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 65923-155 | 65923-155-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CAMPHOR (NATURAL) | N20HL7Q941 | ACTIB |
| MENTHOL | L7T10EIP3A | ACTIB |
| METHYL SALICYLATE | LAV5U5022Y | ACTIB |
| BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | IACT |
| GLYCERYL ROSINATE | SD112V492J | IACT |
| NATURAL LATEX RUBBER | 2LQ0UUW8IN | IACT |
| POLYBUTENE (1400 MW) | 1NA5AO9GH7 | IACT |
| POLYISOBUTYLENE (1000 MW) | 5XB3A63Y52 | IACT |
| CALCIUM CARBONATE | H0G9379FGK | IACT |
| ALPHA-TOCOPHEROL ACETATE | 9E8X80D2L0 | IACT |
| ZINC OXIDE | SOI2LOH54Z | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM STEARATE | SODIUM STEARATE | QU7E2XA9TG | TABLET / ORAL | 9.48 mg | ||
| POLYBUTENE (1400 MW) | POLYBUTENE (1400 MW) | 1NA5AO9GH7 | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SYSTEM / TRANSDERMAL | 113 mg | ||
| PROPYLENE CARBONATE | PROPYLENE CARBONATE | 8D08K3S51E | OINTMENT / TOPICAL | 3000 mg | ||
| POLYBUTENE (1400 MW) | POLYBUTENE (1400 MW) | 1NA5AO9GH7 | SYSTEM / TRANSDERMAL | 17.87 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SPRAY / TOPICAL | 3665 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | SOLUTION / INTRAVENOUS | 3.11 %w/v | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, COATED / ORAL | 64.8 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | LOTION / TOPICAL | 50 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | FILM / TRANSDERMAL | 58.08 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, EXTENDED RELEASE / ORAL | 4 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL / TRANSDERMAL | 85 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / AURICULAR (OTIC) | 36 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SUSPENSION / AURICULAR (OTIC) | 0.02 %w/w | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / AURICULAR (OTIC) | 0.38 %w/w | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, FILM COATED / ORAL | 300 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | GUM, CHEWING / BUCCAL | 3492 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / TOPICAL | 65000 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, DELAYED RELEASE / ORAL | 20 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL, METERED / TRANSDERMAL | 50 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, DELAYED RELEASE / ORAL | 8.4 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | SUPPOSITORY / RECTAL | 375 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / INTRAVENOUS | 4.02 %w/v | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / RESPIRATORY (INHALATION) | 4.02 %w/v | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL / TOPICAL | 9.3 %w/w | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | INJECTION / SUBCUTANEOUS | 0.02 %w/v | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, EXTENDED RELEASE / ORAL | 229.7 mg | ||
| SODIUM STEARATE | SODIUM STEARATE | QU7E2XA9TG | TABLET, DELAYED RELEASE / ORAL | 10 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, CHEWABLE / ORAL | 1650 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET / ORAL | 793 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SYSTEM / TOPICAL | 7 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | FILM, SOLUBLE / ORAL | 14 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, SPRAY / TOPICAL | 6.89 %w/w | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OINTMENT / TOPICAL | 35 %w/w | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | FILM, EXTENDED RELEASE / TRANSDERMAL | 20.4 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | LOTION / TOPICAL | 16 %w/w | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL / TOPICAL | 29 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / TOPICAL | 213 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | POWDER, DENTIFRICE / DENTAL | 0.5 mg/mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | SOLUTION / RESPIRATORY (INHALATION) | 3.11 %w/v | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | INJECTION, SUSPENSION / SUBCUTANEOUS | NA | ||
| SODIUM STEARATE | SODIUM STEARATE | QU7E2XA9TG | TABLET, ORALLY DISINTEGRATING / ORAL | 0.85 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE / ORAL | 349.9 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / VAGINAL | 50 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d5d14104-ac5e-55c6-e053-2a95a90ac86d | fc23a69c-d311-4e96-9cf4-a8591a1fac3a | 2022-01-17 | Warnings | fc23a69c-d311-4e96-9cf4-a8591a1fac3a |
Adverse event summaries are temporarily unavailable. Other product information remains available.